Your browser doesn't support javascript.
loading
Drug testing of monodisperse arrays of live microdissected tumors using a valved multiwell microfluidic platform.
Lockhart, Ethan J; Horowitz, Lisa F; Rodríguez, Adán; Zhu, Songli; Nguyen, Tran; Mehrabi, Mehdi; Gujral, Taranjit S; Folch, Albert.
Afiliación
  • Lockhart EJ; Department of Bioengineering, University of Washington, Seattle, USA. ejl17@uw.edu.
  • Horowitz LF; Department of Bioengineering, University of Washington, Seattle, USA. ejl17@uw.edu.
  • Rodríguez A; Department of Bioengineering, University of Washington, Seattle, USA. ejl17@uw.edu.
  • Zhu S; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, USA.
  • Nguyen T; Department of Bioengineering, University of Washington, Seattle, USA. ejl17@uw.edu.
  • Mehrabi M; L&T Technology Services, Meta Reality Labs, USA.
  • Gujral TS; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, USA.
  • Folch A; Department of Bioengineering, University of Washington, Seattle, USA. ejl17@uw.edu.
Lab Chip ; 24(10): 2683-2699, 2024 05 14.
Article en En | MEDLINE | ID: mdl-38651213
ABSTRACT
Cancer drug testing in animals is an extremely poor predictor of the drug's safety and efficacy observed in humans. Hence there is a pressing need for functional testing platforms that better predict traditional and immunotherapy responses in human, live tumor tissue or tissue constructs, and at the same time are compatible with the use of mouse tumor tissue to facilitate building more accurate disease models. Since many cancer drug actions rely on mechanisms that depend on the tumor microenvironment (TME), such platforms should also retain as much of the native TME as possible. Additionally, platforms based on miniaturization technologies are desirable to reduce animal use and sensitivity to human tissue scarcity. Present high-throughput testing platforms that have some of these features, e.g. based on patient-derived tumor organoids, require a growth step that alters the TME. On the other hand, microdissected tumors (µDTs) or "spheroids" that retain an intact TME have shown promising responses to immunomodulators acting on native immune cells. However, difficult tissue handling after microdissection has reduced the throughput of drug testing on µDTs, thereby constraining the inherent advantages of producing numerous TME-preserving units of tissue for drug testing. Here we demonstrate a microfluidic 96-well platform designed for drug treatment of hundreds of similarly-sized, cuboidal µDTs ("cuboids") produced from a single tumor sample. The platform organizes a monodisperse array of four cuboids per well in 384 hydrodynamic traps. The microfluidic device, entirely fabricated in thermoplastics, features 96 microvalves that fluidically isolate each well after the cuboid loading step for straightforward multi-drug testing. Since our platform makes the most of scarce tumor tissue, it can potentially be applied to human biopsies that preserve the human TME while minimizing animal testing.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ensayos de Selección de Medicamentos Antitumorales / Dispositivos Laboratorio en un Chip / Antineoplásicos Límite: Animals / Humans Idioma: En Revista: Lab Chip Asunto de la revista: BIOTECNOLOGIA / QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ensayos de Selección de Medicamentos Antitumorales / Dispositivos Laboratorio en un Chip / Antineoplásicos Límite: Animals / Humans Idioma: En Revista: Lab Chip Asunto de la revista: BIOTECNOLOGIA / QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido